Mechanistic Biological Insights into the Effects of Resveratrol and Nano-Resveratrol on EAT-Induced Hepatorenal Damage Authors: Nada Oršolić, Snježana Ramić, Ivana Turk, Daniela Ančić Published: 2026 ABSTRACT Background/Objectives: Malignant ascites is characterized by extensive tumor dissemination within the peritoneal cavity, abnormal fluid accumulation, and progressive multiorgan dysfunction, including hepatic and renal impairment. Methods: The present study was conducted to evaluate the protective effects of resveratrol (RSV) and its nanocrystal formulation (NANO-RSV) at doses of 25 and 50 mg/kg against Ehrlich ascites tumor (EAT)-induced hepatic and renal injury by assessing proliferating cell nuclear antigen (PCNA) expression and apoptosis/necrosis rates, which are key indicators of tissue injury, repair, and regeneration. In addition, microvessel density (MVD) was evaluated in peritoneal tumor tissue, liver, and kidneys to assess angiogenesis and tissue remodeling, while macrophage polarization in the spleen was examined to determine the immunomodulatory effects of RSV and NANO-RSV. Results: Resveratrol and its nano formulations acted as potent inhibitors of EAT cells growth through downregulation of PCNA expression, leading to increased tumor cell death via apoptosis and secondary necrosis. In EAT-bearing mice, the hypoxic microenvironment was associated with increased PCNA expression, enhanced angiogenesis, and reduced apoptosis in hepatic tissue. In contrast, treatment with resveratrol and nano-resveratrol reduced PCNA expression, increased apoptotic activity, suppressed angiogenesis, and induced hepatic steatosis. Progression of steatosis, particularly in resveratrol-treated animals, was associated with impaired hepatic regenerative capacity. In the kidneys, elevated PCNA expression and increased cell death indicated active tissue injury accompanied by compensatory proliferative responses. Furthermore, increased splenic arginase-1 activity correlated with enhanced tissue damage and activation of M2 macrophage-mediated repair mechanisms. Conclusions: In conclusion, resveratrol exhibits significant antitumor activity but may induce organ toxicity, whereas its nanocrystals formulation demonstrates improved safety while maintaining efficacy. Enhanced stability, bioavailability, and sustained-release properties of nano-resveratrol contribute to reduced hepatic and renal injury compared with native resveratrol. 1. Introduction Carcinogenesis is a multistep process through which normal cells undergo transformation into a malignant phenotype. Cancer is widely recognized as a major disease of modern society and is characterized by distinct functional capabilities acquired during cellular transformation. These hallmarks include sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, induction of angiogenesis, and activation of invasion and metastasis [1]. Genomic instability, particularly within a chronic inflammatory microenvironment, is considered a key enabling factor underlying these processes [1]. Solid tumors arise in organs such as the breast, prostate, lung, colon, and ovary, and account for approximately 80% of all malignancies [2,3]. Malignant ascites (MA), defined as the pathological accumulation of fluid containing malignant cells within the peritoneal cavity, occurs in approximately 10% of all ascites cases and is associated with a poor prognosis. It is a frequent complication of advanced-stage cancers and is linked to markedly reduced survival, typically not exceeding 20 weeks after diagnosis, as well as significant impairment in quality of life [4,5,6]. Malignant ascites is most commonly associated with ovarian, gastrointestinal, uterine, and breast cancers. Clinically, it is characterized by extensive tumor dissemination, metastasis, and proliferation within the peritoneal cavity, accompanied by abnormal fluid accumulation. The presence of ascites contributes to substantial morbidity, manifesting as abdominal pain, distension, anorexia, fatigue, dyspnea, and progressive multi-organ dysfunction, including hepatic and renal failure [7]. Ascites formation is driven by multiple mechanisms, including impaired lymphatic drainage due to tumor obstruction, increased peritoneal capillary permeability, and enhanced angiogenesis. VEGF plays a central role by promoting both vascular permeability and neovascularization [8,9,10]. The progression of malignant ascites is further influenced by genetic and epigenetic alterations, oxidative stress associated with reactive oxygen species (ROS), and impaired immune surveillance. Tumors recruit circulating monocytes and induce their differentiation into tumor-associated macrophages (TAMs), which contribute to tumor progression and fluid accumulation [11,12,13]. Experimental models such as the Ehrlich ascites tumor (EAT) exhibit key features including rapid tumor growth, pronounced neoangiogenesis, inflammation, increased vascular permeability, and elevated vascular endothelial growth factor (VEGF) levels [9,10,11,12,13,14]. These characteristics closely resemble those observed in human malignancies, including breast, advanced epithelial ovarian, and intra-abdominal cancers as well as extra-abdominal tumors such as lymphoma and lung cancer. Tumor cell infiltration and cancer-associated inflammation induce endothelial damage and increase vascular permeability. Malignant and stromal cells secrete bioactive mediators such as VEGF, interleukin-6 (IL-6), matrix metalloproteinases (MMPs), tumor necrosis factor (TNF), vascular permeability factor (VPF), and cell adhesion molecules (CAMs), promoting neovascularization and tumor progression. Increased vascular permeability elevates the concentration of proteins, including serum proteins and low-molecular-weight proteins, as well as tumor-secreted factors, amino acids, lipids, fatty acids, electrolytes, and minerals in the peritoneal cavity, thereby increasing colloid osmotic pressure and facilitating fluid accumulation [11,12,13]. Accumulation of EAT cells and ascitic fluid leads to severe pathological consequences, including oxidative stress, liver and kidney dysfunction, and high mortality. EAT cells exhibit resistance to cell death, driven by metabolic adaptation and a hypoxic microenvironment that promotes TAM accumulation. These macrophages, predominantly of the pro-tumor M2 phenotype, enhance angiogenesis and immunosuppression, partly through VEGF release. Tumor aggressiveness and resistance to apoptosis in the ascitic form are also associated with increased expression of heat shock proteins 70 and 90 (HSP70 and HSP90), which facilitate the survival, rapid proliferation, and chemoresistance of Ehrlich ascites tumor (EAT) cells [11,12,13,14,15,16]. Furthermore, excessive production of reactive oxygen species (ROS) by both tumor and inflammatory cells compromises the antioxidant defense capacity of surrounding tissues, leading to oxidative damage in the liver, kidneys, and spleen [7,9]. Consequently, physiological organ functions are impaired, while ROS-induced DNA damage triggers apoptotic cell death. In addition, rapid tumor growth and the development of ascites induce systemic stress, stimulating extramedullary hematopoiesis, which results in splenomegaly, increased macrophage infiltration of the spleen, and compromised splenic immune function [17,18]. The spleen is an important site of extramedullary hematopoiesis that generates immunosuppressive myeloid cells in tumor-bearing mice [19]. Despite advances, the mechanisms underlying immune regulation, angiogenesis, ascites formation, and associated organ damage in Ehrlich ascites carcinogenesis remain incompletely understood. Targeting TAMs or modulating oxidative stress using antioxidants such as caffeic acid, tannic acid, and ursolic acid has been shown to inhibit M2 polarization and suppress EAT-associated angiogenesis [11,12,13,14]. Due to its well-documented antioxidant, anti-inflammatory, immunomodulatory, hepatoprotective, anticancer, anti-atherosclerotic, and antidiabetic properties, resveratrol has emerged as a promising candidate for cancer therapy [1,15,16,20,21,22]. Resveratrol, a natural polyphenol found in grapes and berries, exerts pleiotropic anticancer effects, including suppression of tumor growth through induction of apoptosis, regulation of the cell cycle, inhibition of aerobic glycolysis in cancer cells, and modulation of inflammation, angiogenesis, and metastasis, as well as enhancement of the efficacy of conventional chemotherapies through interactions with cancer stem cells and the tumor microenvironment [15,16,21,22]. Resveratrol exhibits a context-dependent “double-edged” effect on ROS [23]. In cancer cells, it predominantly acts as a pro-oxidant, increasing ROS levels (e.g., hydrogen peroxide), which enhances oxidative stress, activates p53 signaling, and induces apoptosis. In contrast, in normal cells, it functions as an antioxidant by scavenging free radicals and activating the Nrf2 pathway, thereby protecting against oxidative damage [23]. Several studies have reported that, depending on the administered dose and the chemical properties of the surrounding environment, trans-resveratrol can undergo oxidation to generate semiquinone intermediates and a relatively stable 4′-phenoxyl radical. These reactive intermediates ultimately promote ROS generation, thereby conferring pro-oxidant properties to the compound. Its pro-oxidant effects are primarily mediated through the mobilization of endogenous copper ions that accumulate in the blood serum, solid tumor tissues, and ascitic fluid in various malignancies, including DNA-bound copper ions [21,24,25]. However, the clinical application of resveratrol is limited by its low bioavailability due to poor absorption, rapid metabolism, and rapid elimination. To address these limitations, various strategies have been explored, including chemical modification, prodrug development, and incorporation into lipid- and polymer-based delivery systems such as nanoparticles, micelles, and vesicles. Among these strategies, nanocrystal formulations have emerged as a promising approach, as flavonoid nanocrystals have demonstrated enhanced bioavailability and improved pharmacological efficacy in both in vitro and in vivo studies [16,21]. In our previous study [21], administration of resveratrol and its nanocrystal formulation significantly reduced tumor cell proliferation within the peritoneal cavity, ascites volume, and peritoneal vascularization, while exhibiting apparently low systemic toxicity. However, histopathological analysis revealed more pronounced hepatocellular necrosis, apoptosis, fibrosis around the central vein, and mild fatty degeneration in the resveratrol group compared to the nanocrystal formulation. Renal alterations, including inflammation, proximal tubular necrosis, and glomerular swelling, were also observed, along with slight increases in biochemical parameters in both treatment groups [21]. As explained above, the unexpected observation of liver and kidney injury following treatment prompted us to further investigate the extent of damage to normal tissues despite the pronounced antitumor response. Although resveratrol and its nanocrystal formulation exhibited significant antitumor activity, no significant differences in overall animal survival were observed compared with the control group. We believe that these findings raise an important clinically relevant question regarding the balance between therapeutic efficacy and potential toxicity. In this context, although a substantial body of evidence supports the protective effects of resveratrol in various disease models, relatively few studies have investigated its potential toxicity, particularly in the setting of malignant ascites. Given that resveratrol and its nanocrystals may induce damage not only to tumor cells but also to adjacent healthy tissues, understanding and quantitatively characterizing the morphological and structural changes associated with resveratrol- and nanocrystal-induced liver and kidney injury is clinically important. Such knowledge may facilitate the identification of potential toxic effects, improve the safety profile of these formulations, and enable optimization of their antitumor efficacy while preserving normal tissue integrity. This study represents a secondary analysis of the same animal samples and provides a quantitative evaluation of liver and kidney injury following treatment with resveratrol and its nanocrystals, with particular emphasis on the altered tumor microenvironment and metabolic stress induced by the Ehrlich ascites tumor (EAT). These effects were evaluated by analyzing proliferating cell nuclear antigen (PCNA) expression and the rates of apoptosis and necrosis as interconnected indicators of tissue injury, repair, and regeneration. In addition, microvessel density (MVD) was assessed as a key indicator of angiogenesis, which is essential for supplying oxygen and nutrients to tissues, facilitating the trafficking of immune cells, promoting tissue repair, and contributing to the restoration of damaged tissue and the maintenance of tissue homeostasis. Furthermore, the immunomodulatory effects of resveratrol and its nanocrystals were evaluated by determining the levels of nitric oxide (NO) and arginase-1 (Arg1), which serve as key indicators of macrophage functional status in the spleen. 2. Materials and Methods 2.1. Materials Trans-resveratrol (RSV) was purchased from ACEF Spa (Azienda Chimica e Farmaceutica, Fiorenzuola D’Arda, Italy), Pluronic® F127 from Sigma Aldrich (Chemie GmbH, Steinheim, Germany), and dimethyl sulfoxide (DMSO) from Sigma Aldrich (Chemie GmbH, Steinheim, Germany). 2.2. Preparation and Characterization of Resveratrol Nanocrystals 2.2.1. Preparation of Resveratrol Nanocrystal Suspension Resveratrol nanocrystals were prepared at the Department of Pharmaceutical Technology, Faculty of Pharmacy and Biochemistry, University of Zagreb, using a modified miniature-scale wet milling method, as previously described [21]. Briefly, milling was performed in a round glass vial (12 × 35 mm) containing five cylindrical magnetic stir bars (6 × 10 mm each). A mixture of yttria-stabilized zirconium oxide beads with three different diameter ranges (0.1, 0.2, and 0.4–0.6 mm, in equal proportions) was used as the milling medium at a bead-to-batch weight ratio of 3:5 (w/w). Stirring was carried out using a magnetic stirrer (Magnetic Stirrer MIX 15 eco, Berlin, Germany). The biocompatible polymer Pluronic® F127 was used as a stabilizer for the RSV nanocrystal suspension, as previously reported [21]. The RSV nanocrystal suspension was prepared with a composition of 5% (w/w) RSV and 1% (w/w) Pluronic® F127. Milling was performed at a stirring speed of 350 rpm for 24 h at room temperature. 2.2.2. Characterization of Resveratrol Nanocrystals The average particle size and polydispersity index (PDI) of resveratrol nanocrystals were determined by photon correlation spectroscopy using a Zetasizer Nano ZS instrument (Malvern Instruments, Malvern, UK). Samples were appropriately diluted with water for injection (Aqua pro, B. Braun Adria d.o.o., Zagreb, Croatia) and measured in triplicate at 25 °C. The morphology of the resveratrol nanocrystals was analyzed by transmission electron microscopy (TEM). The nanosuspension was diluted four-fold with distilled water, deposited onto a copper grid, and examined using a Zeiss EM10A transmission electron microscope (Zeiss, Göttingen, Germany). The preparation method and physicochemical characteristics of the resveratrol nanocrystals have been described previously by Ančić et al. [21]. 2.3. Experimental Animals and Ethics Statement The Swiss albino outbred mouse strain obtained from the Department of Animal Physiology, Faculty of Science, University of Zagreb, was used in this study. During the study, male mice, aged approximately 2 months, weighing 20–25 g, were kept in cages under standard conditions, including a daily rhythm of 12 h of light or darkness at room temperature of 25 °C, and controlled air humidity (60%). Animals were fed with standard food for laboratory animals (Standard Diet GLP, 4RF21, Mucedola, Settimo Milanese, MI, Italy) with water ad libitum. The experimental protocol was approved by the Ethics Committee (Faculty of Science, University of Zagreb, Croatia; permit: 251-58-10617-18-2 of 8 June 2018). All animal studies were performed in accordance with the guidelines of the Republic of Croatia (Animal Protection Act, NN 102/17, 32/19; Ordinance on the Protection of Animals Used for Scientific Purposes, NN 55/13, 37/17, 116/19) and in accordance with the Guide for the Care and Use of Laboratory Animals, DHHS (NIH) Publ. # 86–23, National Research Council, 2011. The study was conducted in accordance with the ethical and legal standards of the European Union and the Republic of Croatia, as well as in compliance with the ARRIVE guidelines. 2.4. Ehrlich Ascites Tumor Model (EAT) EAT, originally derived from murine mammary tissue, is a transplantable, poorly differentiated, hyper-diploid malignancy with 100% tumorigenicity. It grows in ascitic form (liquid) or solid form. The experimental EAT model reproduces an important aspect of many human malignancies, accumulation of ascitic fluid in the abdominal cavity. Ehrlich ascites tumor (EAT) cells were maintained in vivo by serial intraperitoneal (ip) passage in Swiss albino mice at 7–9-day intervals. To collect the cells, the abdominal cavity was rinsed with 3 mL of saline, followed by gentle massage of the abdominal wall. An incision was then made, and the peritoneal fluid was collected using a Pasteur pipette. Cells obtained from the peritoneal fluid were diluted with saline (0.9% sodium chloride solution) to obtain a final concentration of 2.5 × 106 EAT cells/0.5 mL. The total number and viability of EAT cells were determined using Trypan Blue dye and counting in a Bürker–Türk chamber. Cell viability was calculated using the following equation:Viability of EAT cells (%) = (No. of viable cells)/(Total No. of viable and dead cells) × 100 A cell viability threshold of 95% or higher was considered acceptable for further experiments. 2.5. Experimental Design and Animal Treatment Before the experiment, all animals were weighed and randomly assigned after EAT cells inoculation into five groups: (a) control EAT, (b) resveratrol nanocrystals at 50 mg/kg bw (NANO-RSV 50), (c) resveratrol nanocrystals at 25 mg/kg bw (NANO-RSV 25), (d) resveratrol at 50 mg/kg bw (RSV 50), and (e) resveratrol at 25 mg/kg bw (RSV 25). DMSO was used as the solvent due to the high solubility of resveratrol in organic solvents, and the doses were selected based on previous studies [26]. The selected doses of resveratrol (25 and 50 mg/kg administered every other day) are consistent with those commonly used in experimental mouse studies, correspond to human equivalent doses of approximately 60–140 mg/day, and fall within the range considered safe and clinically relevant in human studies. Therefore, the selected dosing regimen is scientifically justified and translationally relevant [27]. Animals were treated intraperitoneally every other day for 14 days with either 0.5 mL water for injection (control) or resveratrol nanocrystals/resveratrol solution at doses of 25 or 50 mg/kg bw. Based on a previous pilot study (unpublished data), no differences were observed between the control group and animals treated with water for injection containing either 1% (v/v) DMSO or 1% (w/w) Pluronic® F127. Therefore, these vehicle control groups were excluded from further experiments. On day 15, six animals per group were euthanized 24 h after the final treatment by intraperitoneal overdose of Narketan®10 (100 mg/kg bw) and Xylapan® (5 mg/kg bw), and by cervical dislocation. Ascitic fluid, serum, liver, and kidney tissues collected in a previous study were used for the present analyses. 2.6. Monitoring of Body Weight Changes Animals were individually marked and weighed before the start of and during the experiment. They were assigned to experimental groups with comparable initial body weights (±2 g). Based on individual body weight, the administered doses of each formulation were calculated for each group. Body weight was subsequently recorded every five days during the experiment to monitor weight gain or loss relative to the control group. Measurements were performed using a digital balance (ABS 220-4; Kern & Sohn, Balingen, Germany). The percentage change in body weight was calculated using the following equation:Percentage change in weight = final body weight − initial body weight/final body weight × 100. 2.7. Organ Index Calculation Organ indices (organ weight relative to body weight) are widely used in experimental oncology and toxicology as sensitive indicators of pathological alterations associated with tumor progression and treatment effects. Changes in liver and kidney indices may reflect tumor burden, organ hypertrophy, inflammation, edema, or treatment-related toxicity [28,29]. The organ (liver, spleen and kidney) indices were calculated according to the following equation:The organ index (%) = m (liver, spleen or kidney weight [g])/m (body weight [g]) × 100, where m (liver, spleen or kidney) is the weight of the liver or the kidneys, m (body) is the body weight of the mouse. 2.8. Measurement of Nitric Oxide (II) Level and Arginase 1 Activity Nitrite (NO2−) production was determined by the Griess assay, and arginase activity was measured using the Arginase Activity Assay Kit (MAK112, Sigma-Aldrich, St. Louis, MO, USA) in spleen macrophages. Spleen macrophages were isolated according to the method previously described [11,12,13]. Briefly, spleens were processed into single-cell suspensions, and mononuclear cells were isolated using Lymphoprep (Nyegaard, Oslo, Norway). After 24 h of incubation in DMEM supplemented with 10% FCS, the culture supernatants and adherent macrophages were collected and stored at −20 °C until analysis of nitrite (NO2−) production and arginase activity. Because nitric oxide is highly unstable, its production was assessed indirectly by measuring nitrite (NO2−) and nitrate (NO3−), the major stable oxidation products of NO. Nitric oxide levels were determined in spleen macrophages using the Griess Reagent System (Promega, Madison, WI, USA). The assay is based on the reaction of nitrite with sulfanilamide and N-(1-naphthyl)ethylenediamine dihydrochloride under acidic conditions (phosphoric acid), resulting in the formation of a colored azo compound with maximum absorbance at 540 nm. Absorbance was measured using an AO Absorbance Microplate Reader (Azure Biosystems, Dublin, CA, USA). A sodium nitrite standard curve (0–100 μM) was prepared from a 0.1 M stock solution dissolved in distilled water. Nitrite concentrations in the samples were calculated from the standard curve and expressed as μM. Arginase 1 activity was determined in spleen macrophages using the Arginase Activity Assay Kit (MAK112; Sigma-Aldrich, St. Louis, MO, USA), according to the manufacturer’s instructions. In this assay, urea produced by arginase-mediated hydrolysis of L-arginine reacts with the assay reagents to generate a colored product, the intensity of which is proportional to arginase activity. One unit of arginase activity is defined as the amount of enzyme that catalyzes the conversion of 1 μmol of L-arginine to ornithine and urea per minute at pH 9.5 and 37 °C. 2.9. Histological Analysis 2.9.1. Preparation of Histological Sections Ehrlich ascites tumor (EAT) cell suspension was fixed in 10% neutral buffered formalin for 6 h. After fixation, the supernatant was removed, and the cell pellet was washed with phosphate buffer. A 1% histological agar solution was prepared by dissolving agar in deionized water using a microwave oven. After cooling to below 60 °C, the agar solution was mixed with the EAT cell pellet. Following gelling for several hours at 4 °C, the agar cell block was placed into histological cassettes and processed for paraffin embedding according to a routine laboratory protocol. Immediately after euthanasia, tissue samples (peritoneum, liver, and kidneys) were rinsed in physiological saline and fixed in Bouin’s solution for 24 h. The tissues were then trimmed to approximately 2 × 1 × 0.5 cm and post-fixed in 10% neutral buffered formalin for an additional 24–48 h. Subsequently, the samples were placed in plastic cassettes and processed for paraffin embedding using a standard laboratory protocol. Three sections of 3 µm thickness were cut from each paraffin block (cell blocks and tissue blocks). One section was routinely stained with hematoxylin and eosin (HE) for histological evaluation and blood vessel quantification, whereas the remaining sections were mounted on positively charged microscope slides for subsequent immunohistochemical analysis. 2.9.2. Immunohistochemical Staining Paraffin-embedded tissue sections (2–3 μm thick) were mounted on silanized glass slides and dried at 60 °C for 40 min. Before immunohistochemical staining, the tissue sections were deparaffinized, rehydrated, and subjected to heat-induced antigen retrieval in Dako EnVision™ FLEX Target Retrieval Solution (high pH, pH 9.0) using a PT Link instrument (Dako, Glostrup Hovedstaden, Denmark) at 97 °C for 20 min. After cooling to room temperature, the slides were rinsed with wash buffer. Immunohistochemical staining was performed using an automated staining system (Autostainer Link 48, Dako, Denmark) with the EnVision™ FLEX/HRP detection system (K8010, Dako, Denmark). Cell proliferation was evaluated using a mouse monoclonal anti-proliferating cell nuclear antigen (PCNA) antibody (clone PC10; Dako, Denmark) at a dilution of 1:200. Antigen–antibody complexes were visualized using a horseradish peroxidase (HRP)-conjugated secondary antibody linked to a dextran polymer backbone. Immunoreactivity was detected with 3,3′-diaminobenzidine (DAB) chromogen for 10 min, resulting in a brown reaction product at sites of antigen expression. The sections were counterstained with hematoxylin to visualize tissue morphology. Finally, the slides were dehydrated through graded ethanol solutions, cleared in xylene, and mounted with coverslips using a permanent mounting medium. 2.9.3. Detection of Proliferating Cell Nuclear Antigen (PCNA) Immunoreactivity Cell proliferative activity is an important indicator of tumor aggressiveness and provides valuable information regarding tumor progression and prognosis. Proliferating cell nuclear antigen (PCNA), a nuclear protein involved in DNA replication and repair, is widely used as a marker of cell proliferation. In the present study, PCNA immunohistochemistry was used to evaluate the proliferative activity of EAT cells as well as the regenerative and proliferative responses in liver and kidney tissues. Strong nuclear PCNA immunoreactivity indicates cell proliferative activity, while weak PCNA expression usually indicates basal cell activity. Only cells exhibiting strong nuclear PCNA immunoreactivity were considered positive. To minimize observer bias, PCNA-positive cells were independently evaluated by two experienced pathologists who were blinded to the allocation of samples to the experimental groups. For each animal, the total number of PCNA-positive cells was determined by counting positive cells in 10 high-power fields (HPFs) at 400× magnification. The mean count obtained by the two observers was used as the final value for each animal, while the minimum and maximum counts are presented in the tables. Group means were then calculated from the individual animal values and are presented as the mean ± standard error (SE). Representative photomicrographs were acquired at ×100 or ×200 magnification using a light microscope equipped with a digital camera. 2.9.4. Quantitative Assessment of Vascularization Histological sections were examined using a light microscope (Axio Star, Zeiss, Göttingen, Germany). Representative photomicrographs were captured using an AxioCam 105 color digital camera (Carl Zeiss Microscopy GmbH, Göttingen, Germany) and analyzed with Zeiss ZEN Lite/Blue software version 2.3. (Zeiss, Göttingen, Germany) for morphometric evaluation. Microvessel density (MVD) was determined in peritoneal, liver, and kidney tissues according to previously described methods [11,12,13]. Briefly, areas exhibiting the highest degree of vascularization (“hot spots”) were identified at low magnification, and microvessels were subsequently counted in selected high-power fields. The mean microvessel count was used to calculate the MVD for each sample. 2.9.5. Analysis of Cell Death in Tumor, Liver, and Kidney Tissues To evaluate the potential toxicity of resveratrol nanocrystals, the numbers of proliferating and dead cells were quantified in EAT tissue, as well as in liver and kidney samples. Apoptotic cells were identified based on characteristic morphological features, including cellular rounding and shrinkage, increased cytoplasmic eosinophilia, nuclear chromatin condensation, particularly along the nuclear envelope in a crescent-shaped pattern, membrane blebbing, and the formation of apoptotic bodies. Necrotic cells were identified by morphological features including cellular swelling, cytoplasmic eosinophilia, loss of plasma membrane integrity, cellular lysis, nuclear pyknosis, and irregular chromatin condensation or fragmentation. Necrotic changes were frequently associated with inflammatory cell infiltration, which is generally absent in apoptosis [11,12,13,14]. Cell death was assessed by evaluating the morphological features of apoptosis and necrosis. A total of 1000 cells per sample were examined in randomly selected high-power fields (400×), and the number of apoptotic and necrotic cells was recorded. To minimize observer bias, cell counts were performed independently by two experienced pathologists who were blinded to the allocation of samples to the experimental groups. The mean count obtained by the two observers was used as the final value for each animal, while the minimum and maximum counts are presented in the tables. Group means were then calculated from the individual animal values and are presented as the mean ± standard error (SE). Because the morphological distinction between apoptotic and necrotic cells can be difficult in routine histological sections, particularly when transitional forms of cell death are present, both types of cell death were combined for quantitative analysis. Therefore, the total number of cells exhibiting apoptotic or necrotic morphological characteristics was considered as the number of dead cells. A semiquantitative assessment was performed by calculating the cell death index (CDI) as follows:CDI (%) = (Number of apoptotic and necrotic cells/Total number of counted cells) × 100%. 2.10. Statistical Analysis Statistical analyses were performed using STATISTICA 13 software (StatSoft, Tulsa, OK, USA). Data are presented as the mean ± standard error of the mean (SE). Differences among independent groups were evaluated using the nonparametric Kruskal–Wallis test. When the Kruskal–Wallis test indicated a significant overall difference, post hoc multiple comparisons of mean ranks were performed to identify pairwise differences between groups. Statistical significance was set at a two-tailed p < 0.05. A total of six animals per group were used. The sample size was estimated by an a priori power analysis using the freely available online Sample Size and Power Analysis Calculator “StatsCalculators” for a one-way ANOVA, assuming 80% power, α = 0.05, and an effect size of 0.7. 3. Results 3.1. Resveratrol and Its Nanocrystal Inhibit Tumor Cell Proliferation by Reducing PCNA Expression and Inducing Cell Death in EAT Cells PCNA (proliferating cell nuclear antigen) plays multiple roles in cancer development, including the regulation of cell proliferation, DNA replication, and DNA repair, and serves as a widely used biomarker and therapeutic target. Increased expression of PCNA, a marker of DNA replication and cell proliferation, in EAT cells of the control group indicates rapid and uncontrolled proliferation of tumor cells within the mouse peritoneal cavity (Table 1, Figure 1). In addition to increased cell proliferation, the control group is characterized by higher blood vessel density and a very low level of cell death (apoptosis and necrosis) (Table 2 and Table 3). Nanocrystals of resveratrol (NANO-RSV) and Resveratrol (RSV) act as a potent natural anticancer compound that inhibits cell proliferation by targeting PCNA, inducing a high percentage of cell death compared to the control (Table 1). The percentage of cell death in the NANO-RSV-treated groups at doses of 25 and 50 mg/kg was 220.21% and 374.33%, respectively, while in the RSV-treated groups it was 164.34% and 465.20%, respectively, relative to 100% in the control group (Table 2). The tested compounds decreased microvessel density to 54–70% of the control value, with control mice representing 100% microvessel density (Table 3). 3.2. Effect of Resveratrol and Its Nanocrystals on EAT-Induced Increased PCNA Expression in the Liver Ascitic fluid contains inflammatory and cancer cells, which, together with the fluid itself, establish a destructive feedback loop with the liver, leading to hepatic complications, functional impairment, and often progression to cirrhosis and portal hypertension. Ascites can cause kidney failure due to severe changes in blood circulation, known as hepatorenal syndrome. Strong nuclear expression of the protein PCNA, essential for DNA synthesis and repair, which is greatly upregulated during the G1 and S phases of the cell cycle, is associated with cell proliferation. Weak immunohistochemical expression of PCNA usually indicates basic cellular activity and routine maintenance rather than active cell division. The livers of control-group mice with ascites are characterized by increased proliferation, enhanced vascularization, and reduced apoptosis, indicating intensified inflammation, fibrosis, and the presence and proliferation of inflammatory and tumor cells in the liver (Table 4, Table 5 and Table 6). Increased angiogenesis plays a key role in the progression of liver cirrhosis, as a leading risk factor for hepatocellular carcinoma (HCC), particularly in the development of complications associated with portal hypertension. PCNA expression in the liver following treatment with NANO-RSV (25 and 50 mg/kg) and RSV was reduced by 25.55–73.15% and 42.20–68.68%, respectively, compared to the control group (Table 4, Figure 2). Microvessel density (MVD) in the liver was 440.50 ± 19.53 (100%) in the control group, whereas in treated animals it was reduced to approximately 60%, ranging from 55.77% to 61.94% (Table 6). The relationship between proliferation and apoptosis in the NANO-RSV and RSV treatment groups was dose-dependent; lower doses were associated with higher proliferation and reduced apoptosis, whereas higher doses resulted in significantly lower PCNA expression and a higher percentage of apoptotic cells compared with the control. The number of apoptotic cells in the NANO-RSV and RSV groups at 50 mg/kg was 212.50 ± 33.96 and 290.67 ± 38.09, respectively, while at 25 mg/kg it was 126.67 ± 26.43 and 67.50 ± 14.92, compared with 10.50 ± 0.96 in the control group (Table 5). 3.3. Resveratrol and Its Nanocrystals Appear to Promote Repair and Remodeling of Active Pathological Kidney Damage Through Increased Proliferation and Apoptosis Interestingly, PCNA expression in the kidney was markedly higher in the RSV and NANO-RSV-treated groups compared with the control. The descending order of PCNA levels was as follows: NANO-RSV at 50 mg/kg (755.67 ± 39.62), NANO-RSV at 25 mg/kg (709.67 ± 16.05), RSV at 50 mg/kg (564.83 ± 32.47), and RSV at 25 mg/kg (480.33 ± 40.92), whereas the control group exhibited a PCNA level of 382.67 ± 12.01 (Table 7, Figure 3). The percentage of cell death (apoptosis/necrosis) was highest in the low-dose NANO-RSV and RSV groups (325.16% and 284.76%, respectively) compared with the 50 mg/kg dose groups (239.64% and 198.02%, respectively), when compared with the control group (100%) (Table 8). In contrast, the number of blood vessels was highest in the control group, whereas treatment with the tested formulations reduced vascular density by approximately 18–30% (Table 9). 3.4. Effect of Resveratrol Nanocrystals and Resveratrol Solution on Organ Index Changes Interestingly, no significant deviations were observed in the liver, spleen, and kidney indexes. Compared to the control group, the liver and spleen indexes were increased only in the group treated with NANO-RSV at a dose of 50 mg/kg, likely due to the accumulation of nanocrystals in macrophages of the reticuloendothelial system. In contrast, treatment with RSV at a dose of 50 mg/kg resulted in a markedly reduced index compared to the NANO-RSV-treated group (Table 10). 3.5. Resveratrol Nanocrystals and a Resveratrol Solution Act on Macrophage Polarization Our previous study demonstrated the effects of resveratrol and its nanocrystals on the polarization of macrophages derived from ascitic fluid and their connection with oxidative stress and tumorigenesis by the analysis of nitric oxide (NO) levels and arginase activity, cytokines and chemokines concentrations, vascular endothelial growth factor (VEGF), and matrix metalloproteinases (MMP-2 and MMP-9). In the present study, we analyzed macrophages isolated from the spleen, a key hematopoietic and immunological organ. It has been shown that increased arginase activity in the spleen represents a critical immunological mechanism, particularly through the induction of arginase 1 (Arg1) in splenic myeloid-derived suppressor cells (MDSCs) under conditions such as acute or chronic inflammation, sepsis, trauma, or cancer [17,18,19]. This upregulation leads to local depletion of L-arginine, thereby suppressing T-cell function and limiting nitric oxide (NO) production, which ultimately facilitates immune evasion by pathological cells. The data presented in Table 11 indicate that both resveratrol (RSV) and its nanocrystal formulation (NANO-RSV) enhanced macrophage activation, as reflected by increased NO production and changes in arginase-1 (Arg1) levels. The highest NO levels were observed in macrophages isolated from animals treated with NANO-RSV and RSV at a dose of 50 mg/kg (3.50 ± 0.55 and 2.04 ± 0.29, respectively), followed by treatment at 25 mg/kg (1.96 ± 0.27 and 1.49 ± 0.38, respectively), compared with the control group (0.47 ± 0.08). Arginase-1 (Arg1) levels were highest in macrophages from animals treated with RSV at doses of 50 and 25 mg/kg, which coincided with the most pronounced histopathological alterations and biochemical changes previously reported by Ančić et al. [21]. 4. Discussion The experimental cancer model based on the induction of Ehrlich tumor cells (EAT) is widely employed to investigate tumorigenic, immunological, and physiological processes, as well as to evaluate novel diagnostic approaches and therapeutic agents, owing to its similarity to pathological and behavioral processes observed in humans. Furthermore, Ehrlich tumors represent a valuable tool for advancing the understanding of the pathogenesis of various advanced-stage cancers, as well as for studying the tumor microenvironment, therapy-associated side effects, and emerging treatment strategies. Numerous literature data have shown that the accumulation of EAT cells and ascitic fluid leads to significant pathological damage, including oxidative stress, severe hepatic and renal dysfunction, and high mortality within a few weeks [4,5,6,7,8,9,10,21]. Ehrlich ascites tumor (EAT) represents an aggressive tumor model that possesses marked resistance to cell death mechanisms, largely driven by metabolic adaptations and a hypoxic microenvironment that promotes the accumulation of tumor-associated macrophages (TAMs) [11,14,15,16]. TAM together with ROS promotes tumor growth and accelerates neoangiogenesis via VEGF release, creating an immunosuppressive microenvironment. This adverse malignant ascites microenvironment, enriched with products of inflammatory and tumor cells, induces hepatic fibrosis and renal injury through the secretion of proinflammatory cytokines, angiogenesis, and metabolic reprogramming [11,12,13,14,15,16,21]. Accordingly, we hypothesized that natural polyphenolic compounds, including resveratrol, with antioxidant activity, capable of reducing oxidative stress and chronic inflammation through free radical scavenging, metal chelation, modulation of endogenous antioxidant enzymes, and suppression of proinflammatory mediators, may be effective in inhibiting tumor growth. Mechanistically, these compounds regulate multiple cancer-associated pathways, leading to cell cycle arrest, induction of apoptosis, inhibition of angiogenesis, and exert a protective effect on the liver and kidneys [15,16,21,30,31,32,33,34,35,36]. Consequently, the aim of the current study is to confirm the mechanisms of the inhibitory effect of resveratrol and its nanocrystals on proliferation, apoptosis/necrosis levels, microvessel density (MVD), and macrophage polarization as key factors in the progression of malignant ascites and the development of a negative microenvironment contributing to liver and kidney damage caused by tumor and/or inflammatory cells. Our data confirm that EAT cells exhibit rapid proliferation and high expression of PCNA (Table 1), and are characterized by markedly pleomorphic and anaplastic morphology, with a high nucleus-to-cytoplasm ratio and nuclei containing loosely organized chromatin and multiple prominent nucleoli (Figure 1). High PCNA expression levels correlate with tumor aggressiveness, poor prognosis, and resistance to therapy [37,38]. Our previous findings confirmed the aggressive growth and high-grade malignancy of EAT by increased tumor size, ascites fluid volume, elevated VEGF and HIF expression, and enhanced MMP activity in non-treated EAT-bearing mice [16,21]. Furthermore, malignant EAT ascites recruit a high number of tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) with pro-tumorigenic functions, thereby contributing to angiogenesis and promoting tumor progression (Table 3). Treatment with resveratrol or its nanocrystals acts as a potent inhibitor of cancer cell proliferation by downregulating PCNA expression, leading to cell death with features of both apoptosis and, subsequently, secondary necrosis, often characterized by the release of nuclear DNA and loss of membrane integrity (Table 2). Resveratrol and its nanocrystal formulations can inhibit tumor growth and angiogenesis by targeting HIF-1α and VEGF pathways [15,16]. In addition, resveratrol, acting as a histone deacetylase (HDAC) inhibitor, can induce cancer cell cycle arrest, differentiation, and apoptosis while suppressing angiogenesis and modulating the immune response [15,16]. Our data confirmed that resveratrol and its nanocrystals, through inhibition of PCNA expression, may contribute to the regulation of cellular signaling, apoptosis, metabolism, and antitumor immunity. According to previous studies [32,33,34,35,36], resveratrol inhibits several oncogenic signaling pathways, including PI3K/Akt/mTOR, Wnt/β-catenin, and NF-κB, all of which are involved in the downregulation of proliferative markers such as PCNA. Since PCNA expression is closely associated with malignant transformation, it may represent a selective target for tumor therapy and is widely used as an immunohistochemical marker of cellular proliferation. Inhibition of PCNA by resveratrol and its nanocrystal formulations opens new perspectives for the clinical application of resveratrol as a chemopreventive agent and anticancer therapeutic. PCNA is a highly conserved protein essential for DNA replication, repair, and scaffold functions in the cytosol. It is expressed in all cells and plays a key role in normal cellular homeostasis [39]. In contrast to liver affected by malignant ascites, normal liver cells exhibit lower PCNA expression; these are non-proliferating, quiescent cells. Malignant ascites can act on liver cells; PCNA expression is markedly higher within liver cells of control group of EAT-bearing mice (Table 4, Figure 2). Prolonged ischemia, fibrosis, and hypoxia in the livers of control EAT-bearing mice further enhance angiogenesis (Table 6) and promote resistance to apoptosis (Table 5). Treatment with resveratrol and resveratrol nanocrystals in EAT-bearing mice reduced PCNA expression levels, increases apoptosis levels, and reduces angiogenesis in liver tissue, reflecting metabolic alterations associated with increased infiltration of tumor and inflammatory cells in the liver and peritoneal cavity (Table 4, Table 5 and Table 6). According to data, resveratrol and its nanocrystals reduce hypoxia-induced expression of HIF-1α and VEGF in malignant ascites [15,16,21], reducing the microvessel density in the liver (Table 6). Resveratrol acts as a dose-dependent modulator of cell death in the liver, typically acting as a hepatoprotective agent at lower concentrations and inducing cell death (apoptosis) in abnormal cells at high concentrations (Table 5). Thus, at concentrations that are suitable for chemopreventive and chemotherapeutic actions, resveratrol may exert a cytotoxic effect on normal cells [40]. The reduced PCNA expression together with increased levels of apoptosis/necrosis in liver tissue suggests impaired hepatocellular proliferative and regenerative capacity, accompanied by enhanced cell death (Table 4 and Table 5). Conversely, increased necrosis of hepatocytes may contribute to inflammation and pathological tissue remodeling during liver injury. The pro-inflammatory environment further enhances oxidative stress and promotes tissue remodeling, including the development of steatosis [41]. Our histological analysis of liver tissue from resveratrol-treated groups revealed moderate steatosis (Figure 2). According to previous findings [42], steatosis affects the proliferative potential of hepatocytes, and the coexistence of steatosis with reduced PCNA expression generally reflects impaired liver regeneration and increased cellular injury. It appears that the progression of steatosis is associated with decreased PCNA expression, which consequently may contribute to the reduced regenerative capacity of the liver. Furthermore, steatosis can lead to reduced vascular density, impaired sinusoidal blood flow, and an increased number of shunting vessels. The lowest number of blood vessels was observed in EAT-bearing mice treated with both doses of resveratrol (Table 6) compared with the untreated EAT-bearing group. We hypothesize that the altered expression of PCNA in the liver is a consequence of dose-dependent increases in hepatocyte death induced by resveratrol and its nanocrystals formulations, along with the progression of steatosis associated with elevated oxidative stress. The reduced PCNA expression in hepatic cells may reflect impaired proliferative capacity due to increased cell death associated with elevated oxidative stress. As previously reported, resveratrol (RSV) exhibits dual redox activity, functioning as either an antioxidant or a pro-oxidant depending on the cellular context, concentration, and time of exposure. Its pro-oxidant effects are primarily mediated through the mobilization of endogenous copper ions, including those bound to DNA [21,24,25]. RSV facilitates copper-driven redox cycling, resulting in the generation of reactive oxygen species (ROS) and electrophilic intermediates capable of inducing diverse forms of DNA damage, such as oxidative base modifications, single- and double-strand breaks, and DNA adduct formation. Notably, the elevated intracellular copper levels, characteristic of many tumor cells, may potentiate this mechanism, thereby contributing to selective cytotoxicity by oxidative stress, proteasome inhibition, or apoptosis. Interestingly, elevated copper (Cu) levels have been detected in the serum and tissues of patients with various malignancies, including colorectal, gallbladder, breast, lung, prostate, liver, pancreatic, and thyroid cancer, compared with healthy individuals [43,44,45,46,47]. In addition, resveratrol can interact with both copper ions and DNA to form a DNA–resveratrol–Cu (II) ternary complex, which promotes oxidative DNA cleavage via Haber–Weiss- and Fenton-type reactions. Therefore, increased oxidative stress may lead to substantial tissue injury in organs such as the liver and kidneys, since the liver serves as the primary reservoir of copper (Cu) in the body, regulating its distribution to peripheral tissues through the bloodstream and its excretion via bile. Disruption of copper homeostasis under conditions of oxidative stress may promote excessive generation of reactive oxygen species (ROS), lipid peroxidation, mitochondrial dysfunction, and cellular damage. Consequently, prolonged oxidative imbalance can impair hepatic and renal function, enhance inflammatory responses, and contribute to tissue degeneration and reduced regenerative capacity [23,24,25]. Liver and kidney damage may occur through the generation of intracellular free Cu(I) ions, which can inhibit enzymatic function by oxidizing cysteine residues in iron–sulfur cluster proteins or by reacting with hydrogen peroxide to produce highly reactive hydroxyl radicals [36,37,47,48]. Hydroxyl radicals are potent oxidizing agents of DNA, leading to mutagenicity and cellular lethality [48]. Meanwhile, copper (Cu) can nonspecifically and directly bind to thiol and amino groups of proteins, thereby disrupting their structural integrity and biological function [47,48,49]. However, excessive copper accumulation in the tumor microenvironment acts as a “double-edged sword” in tumors [49]. On one hand, copper promotes tumor growth; on the other hand, excess copper induces high levels of ROS through the Fenton reaction, leading to severe oxidative damage in proteins, lipids, and DNA. Furthermore, high copper levels can directly or indirectly modulate key apoptotic pathway proteins, leading to programmed cell death. Increased PCNA expression and elevated cell death in the kidneys of EAT-bearing mice treated with resveratrol and its nanocrystal formulations, compared with controls, indicate active renal injury accompanied by compensatory proliferative responses associated with tissue repair or remodeling (Table 7 and Table 8, Figure 3). Interestingly, renal tissue treated with resveratrol nanocrystal formulations exhibited higher PCNA expression than the resveratrol group, suggesting a more pronounced reparative response. Higher doses (50 mg/kg) of both resveratrol and its nanocrystal formulations appear to exert greater renoprotective effects, as indicated by a lower proportion of cells undergoing cell death compared with the low-dose (25 mg/kg) treatments. Previous studies have also reported increased levels of apoptosis during the recovery phase of acute kidney injury [50,51]. According to these findings [50,51], acute renal injury leads to the loss of epithelial cells, ultimately resulting in glomerulosclerosis and tubular atrophy, while interstitial inflammation and fibrosis arise from excessive accumulation of leukocytes and myofibroblasts. Although cell death processes, including apoptosis and necrosis, are essential for the removal of damaged or unwanted cells, excessive activation of these pathways may contribute to pathological renal cell loss (Table 7, Table 8 and Table 9, Figure 3). Nevertheless, irrespective of the administered dose, the percentage of dead cells remained higher in resveratrol and its nanocrystal formulations in EAT-bearing mice compared with the untreated control group, which also exhibited lower PCNA expression (Table 7, Figure 3). Despite the activation of repair mechanisms in resveratrol and its nanocrystal formulation-treated animals, both apoptotic and necrotic cell death may contribute to the loss of functional tubular epithelial cells and to the minor alterations observed in blood biochemical parameters [21]. Renal and hepatic injury may also be exacerbated by tumor cell lysis, as well as by toxins derived from tumor and immune cells, and by elevated levels of cytokines, proteases, and reactive radicals. The tumor microenvironment (TME) is a complex ecosystem surrounding cancer cells that is composed of tumor cells, the extracellular matrix (ECM), innate and adaptive immune cells, inflammatory cells, tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), tumor-associated neutrophils, myeloid-derived suppressor cells (MDSCs), endothelial cells, microvascular networks, and various cytokines and chemokines, all of which may contribute to liver and kidney injury [1,15,16]. The presence of a tumor is also associated with abnormalities in serum electrolytes, including hyponatremia, hypokalemia, hyperkalemia, hypophosphatemia, hypercalcemia, and disturbances in acid–base balance [52,53,54]. These electrolyte imbalances may result from paraneoplastic processes and are associated with poor clinical outcomes and increased mortality. However, resveratrol and nanoresveratrol did not significantly affect liver, spleen, and kidney weight indexes (Table 10). Compared to the control group, the liver and spleen indexes were increased only in the group treated with resveratrol nanocrystal formulations at a dose of 50 mg/kg, likely due to the accumulation of nanocrystals in macrophages of the reticuloendothelial system (Table 10). The spleen is a specialized multifunctional organ essential for primary immune surveillance and a key site of hematopoietic activity, in which macrophages play a critical role in blood filtration, iron homeostasis, and the initiation of immune responses. Emerging evidence indicates that the TME plays a pivotal role in shaping responses to immunotherapy, with tumor-associated macrophages (TAMs), the predominant immune cell population within the TME, strongly associated with poor prognosis, metastatic progression, and therapeutic resistance [15,16]. They have weak antigen-presenting capabilities, and through the secretion of various suppressive factors, they reduce the activity of cytotoxic T cells and natural killer (NK) cells [1,11,12,13,53]. These TAMs promote tumor growth, angiogenesis, and immune evasion, often resulting in adverse clinical outcomes. Nitric oxide (NO) production and arginase activity represent two key opposing pathways in macrophage polarization, defining the functional spectrum between classically activated (M1) pro-inflammatory and alternatively activated (M2) anti-inflammatory macrophages. M1 macrophages induce iNOS, which converts L-arginine into nitric oxide (NO), which is crucial effector molecule for pathogen killing, tumoricidal activity, and maintaining pro-inflammatory responses. M2 macrophages, driven by tumor-derived signals such as hypoxia and cytokine-mediated signaling, express Arg1, which hydrolyzes L-arginine into ornithine and urea. Ornithine is a precursor for polyamines and proline, which promote tissue repair, angiogenesis, and collagen synthesis [11,12,13,14,15,16,21]. We analyzed macrophage polarization in spleen-derived cells and demonstrated that both resveratrol and its nanocrystal formulation stimulate macrophage activation and NO production, confirming the immunomodulatory activity of the tested compounds (Table 11). However, the highest arginase-1 activity was observed in the spleens of animals treated with resveratrol at doses of 50 and 25 mg/kg, which correlates with the most pronounced histological alterations in liver and kidney and changes in biochemical parameters described previously [21]. Elevated splenic arginase activity constitutes a central immunoregulatory mechanism that mediates local L-arginine depletion, resulting in impaired T-cell effector function and reduced nitric oxide (NO) biosynthesis, thereby facilitating immune evasion by pathological cells. In addition, an increased polarization from M1 toward M2 macrophages indicates greater tissue damage induced by resveratrol and the subsequent activation of repair mechanisms. According to findings [55,56], excess copper in TME can suppress macrophage function and promote polarization toward the M2 phenotype, thereby enhancing immunosuppression. In addition, the spleen acts as a source of myeloid cells, including tumor-associated macrophages (TAMs), that are recruited to malignant ascites. In this context, differential arginine metabolism represents a key functional determinant distinguishing M1 from M2 macrophage polarization states. However, according to our findings, these cells may represent myeloid-derived suppressor cells (MDSCs), which, in addition to exhibiting elevated arginase activity, frequently produce increased levels of reactive oxygen species (ROS) and nitric oxide (NO), consistent with previous reports [57]. The synergistic interaction between arginase-1 activity and ROS generation results in the formation of peroxynitrite, thereby further potentiating immunosuppression and exacerbating tissue damage, as reflected by the significantly reduced liver index observed in the resveratrol-treated group of mice bearing EAT (Table 10). Peroxynitrite causes modifications in numerous biomolecules including proteins, lipids, thiols, sulfhydryl groups, DNA bases, and preferentially nitrates tyrosine residues of protein or non-protein origins [1,15,16]. It is known that MDSCs accumulate in the liver and play a complex role in regulating both lipid metabolism and hepatic inflammation, functioning as a double-edged sword by locally suppressing detrimental inflammatory responses while simultaneously exacerbating lipid accumulation and liver injury. Elevated levels of arginase-1 and immunosuppressive cytokines, including IL-10, IL-13, IL-17, TGF-β, and VEGF, in ascites and serum further substantiate the immunosuppressive activity and functional phenotype of myeloid-derived suppressor cells (MDSCs) [17,18,19,21]. VEGF present in the tumor microenvironment is a key driver of MDSC expansion. In addition to VEGF, elevated serum levels of IL-13 are generally associated with tumor-promoting activity and are functionally linked to the immunosuppressive activity of MDSCs within the tumor microenvironment (TME) [21,57,58]. IL-13, together with other cytokines such as IL-4, binds to the IL-4Rα receptor expressed on the surface of MDSCs, thereby activating the STAT6 signaling pathway. Subsequent STAT6 activation significantly enhances the suppressive phenotype and immunoregulatory capacity of MDSCs through the upregulation of arginase-1 and inducible nitric oxide synthase (iNOS). These enzymes mediate the depletion of essential nutrients, particularly L-arginine, which is required for effective T-cell proliferation and effector function [58]. The immunosuppressive vicious cycle is further reinforced by IL-17, whose increased production is driven by elevated levels of IL-23, a cytokine that promotes the differentiation and activation of Th17 and γδT17 cells [21,58,59,60,61]. In turn, IL-17 contributes to the recruitment and enhanced survival of myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment [59]. 5. Conclusions These findings provide further insight into the effects of resveratrol and its nanocrystal formulations on EAT-induced hepatorenal damage, indicating that despite their strong antitumor activity, they may cause hepatic and renal toxicity under certain conditions. Free resveratrol induced more severe hepatotoxicity than the nanocrystal formulation, characterized by hepatocellular necrosis, apoptosis, fibrosis, degeneration, and mild steatosis, along with reduced PCNA expression and impaired liver regeneration. Renal damage in resveratrol-treated EAT-bearing mice was marked by tubular necrosis, glomerular alterations, inflammation, and endothelial dysfunction, accompanied by increased PCNA expression suggesting compensatory repair responses. High-dose resveratrol nanocrystals showed greater protective effects, with enhanced PCNA expression and fewer apoptotic cells. Increased splenic arginase-1 activity indicated activation of M2 macrophage-mediated repair mechanisms. Overall, the pro-oxidative effects of resveratrol within the EAT microenvironment, which is characterized by increased copper levels, may contribute to enhanced ROS generation and subsequent oxidative damage affecting both tumor and normal cells.